Drugs / Bifidobacterium longum

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06347770 Jan 2024 → Mar 2028 expected Zhe Li Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT04082598 Oct 2016 → Sep 2018 Antonio Barone Completed No outcome recorded
Phase not applicable5 trials
NCT07184905 Sep → Oct 2025 Shenzhen People's Hospital Completed No outcome recorded
NCT06639516 Feb → Dec 2025 overdue acute pancreatitis The First Affiliated Hospital of Nanchang University Not yet recruiting No outcome recorded
NCT04639141 Dec 2021 → Apr 2022 anxiety, autism spectrum disorder The University of Queensland Completed No outcome recorded
NCT04706559 Jan → Sep 2021 atopic eczema B.P. Koirala Institute of Health Sciences Completed No outcome recorded
NCT06241222 Jan 2018 → Dec 2021 Third Affiliated Hospital, Sun Yat-Sen University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Bifidobacterium longum “After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105...” NCT06241222
6

“tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days” NCT04082598

“received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd.” NCT06347770

Bifidobacterium longum(BL)” NCT06639516

Bifidobacterium longumNCT04639141

NCT04706559

NCT07184905

Modality Other / unclassified “Prebiotic + Probiotic” NCT04639141
Route Oral “Mode of administration: oral.” NCT04639141